U.S. stocks are rallying after financial markets worldwide got a shot of adrenaline from an encouraging update on U.S.

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...

Key Takeaways Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.The ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration ...

CEO David Ricks told Reuters on Wednesday. Exclusive: Eli Lilly could launch obesity drug in India next year, CEO says Reuters, the news and media division of Thomson Reuters, is the world’s ...

Eli Lilly and Co. CEO David Ricks—IBJ’s newsmaker of the year in 2023—returns to the newsmaker list in 2024 after a year that included a stock price that skyrocketed to an all-time high of $ ...